ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Carrington's DelSite Subsidiary Presents Data On Needle-Free Vaccine Technology
Carrington
Laboratories, Inc. (Nasdaq: CARN) reported today that GelVac(TM), a dry
powder nasal delivery formulation for vaccines, showed both antigen
stabilization and high immunogenic effect in preclinical models. In
addition, ongoing studies of GelVac(TM) formulations incorporating
influenza antigens exhibited the potential for long-term stability during
storage at room temperature.
In a presentation entitled "A Stable Dry Powder Vaccine Formulation
(GelVac(TM)) for Nasal Delivery" at the 2006 American Association of
Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition October 29-
November 2, 2006 in San Antonio, Texas, Babu M. Medi, PhD, Pharmaceutical
Scientist at DelSite Biotechnologies, Carrington's wholly-owed subsidiary,
described preparation and characterization of GelVac(TM) stable dry powder
vaccine formulations for nasal delivery of vaccines using different drying
methods.
The data showed the antigens were protected from activity loss during
the dry powder formulation process, maintaining their potency. In addition,
the GelSite(R) polymer, the key ingredient of GelVac(TM) powder
formulations, exhibited a distinct antigen stabilization effect in addition
to conferring in situ gelling properties, both of which serve to increase
the uptake of active antigens in the nasal cavity.
Equally important, the preservative-free dry powdered formulations
incorporating influenza antigens were shown to be stable for over 18 months
during storage at ambient room temperature (still ongoing). They were also
highly immunogenic, eliciting robust immune responses in animals after
nasal delivery.
GelSite(R) polymer provides an in situ gelling property for optimal
nasal delivery. Upon hydration by nasal fluid, the GelVac(TM) formulation
changes from dry powder particles to wet gel particles, resulting in the
formation of a gel that adheres to nasal mucus, thus maximizing antigen
exposure through prolonged nasal residence time and sustained antigen
release.
An abstract of this presentation can be found on DelSite's website at
http://www.delsite.com/newfiles/sci_pubs.html.
About GelSite(R) Polymer
GelSite polymer is a novel, naturally derived high-molecular-weight
polygalacturonic acid. It possesses distinct chemical and functional
properties proprietary to the Company, including in situ gelling. It is
manufactured under cGMP as a highly pure dry substance.
About GelVac(TM)
GelVac(TM) is a proprietary nasal powder vaccine delivery system based
on the GelSite(R) polymer, the primary functional ingredient that confers
its unique in situ gelling property. The GelVac(TM) system combines the
advantages of dry powder formulations and nasal immunization, including
room temperature stability, prolonged shelf life, and no need for
preservatives, and induction of systemic and mucosal immune responses.
About DelSite
DelSite Biotechnologies, Inc. is a drug delivery and biotechnology
company established to provide the pharmaceutical and biotechnology
industries with novel delivery solutions for vaccines and therapeutic
agents. DelSite is a wholly owned subsidiary of Carrington Laboratories,
Inc. and was formed based on discoveries at Carrington.
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based,
biopharmaceutical and consumer products company currently utilizing
naturally- occurring complex carbohydrates to manufacture and market
products for mucositis, radiation dermatitis, wound and oral care, as well
as to manufacture and market the nutraceutical raw material Manapol(R) and
cosmetic raw material Hydrapol(TM). Carrington also manufactures and
markets consumer products and manufactures quality products for other
companies. Manufacturing operations comply with cGMP standards.
Carrington's technology is protected by more than 130 patents in 26
countries. Select products carry the CE mark, recognized worldwide. For
more information, visit http://www.carringtonlabs.com.
Certain statements in this release concerning Carrington may be
forward- looking. Actual events will be dependent upon a number of factors
and risks including, but not limited to: subsequent changes in plans by the
Company's management; delays or problems in formulation, manufacturing,
distribution, production and/or launch of new finished products; changes in
the regulatory process; changes in market trends; and a number of other
factors and risks described from time to time in the Company's filings with
the Securities & Exchange Commission, including the Form 10-Q, filed August
14, 2006.
Carrington Laboratories, Inc.
http://www.carringtonlabs.com
View drug information on Carrington patch.
Carrington's DelSite filialã prezintã date privind ac-free vaccin tehnologie - Carrington's DelSite Subsidiary Presents Data On Needle-Free Vaccine Technology - articole medicale engleza - startsanatate